UB Paderborn / Katalog / Suche / in CDI

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2178-2186

2020

Volltextzugriff (PDF)

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

The lancet oncology, 2017-06, Vol.18 (6), p.812-822

2017

Volltextzugriff (PDF)

Random CNN structure: tool to increase generalization ability in deep learning

EURASIP journal on image and video processing, 2022-02, Vol.2022 (1), p.1-12, Article 3

2022

Volltextzugriff (PDF)

The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma

International journal of clinical oncology, 2020-11, Vol.25 (11), p.2006-2014

2020

Volltextzugriff (PDF)

Patient experience of medication administration and development of a Patient Experience and Preference Questionnaire (PEPQ) for patients with advanced or metastatic cancer

Frontiers in pharmacology, 2024-03, Vol.15, p.1310546-1310546

2024

Volltextzugriff (PDF)

Outcome of First‐Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma

The oncologist (Dayton, Ohio), 2019-01, Vol.24 (1), p.110-116

2019

Volltextzugriff (PDF)

IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma

Journal of Cancer, 2018-01, Vol.9 (6), p.998-1005

2018

Volltextzugriff (PDF)

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma

Cancers, 2022-02, Vol.14 (5), p.1248

2022

Volltextzugriff (PDF)

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Journal for immunotherapy of cancer, 2020-11, Vol.8 (2), p.e001117

2020

Volltextzugriff (PDF)

CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study

Cancer medicine (Malden, MA), 2023-01, Vol.12 (2), p.1350-1357

2023

Volltextzugriff (PDF)

Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring

Healthcare (Basel), 2022-09, Vol.10 (9), p.1714

2022

Volltextzugriff (PDF)

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Journal for immunotherapy of cancer, 2023-10, Vol.11 (10), p.e007637

2023

Volltextzugriff (PDF)

Developing Symptom Lists for People with Cancer Treated with Targeted Therapies

Targeted oncology, 2021, Vol.16 (1), p.95-107

2021

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Journal of clinical oncology, 2024-01, Vol.42 (1), p.47

2024

Volltextzugriff (PDF)

High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors

Melanoma research, 2018-10, Vol.28 (5), p.435-441

2018

Volltextzugriff (PDF)

Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer

Cancers, 2019-06, Vol.11 (6), p.817

2019

Volltextzugriff (PDF)

From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems

Critical reviews in oncology/hematology, 2024-09, Vol.201, p.104433, Article 104433

2024

Volltextzugriff (PDF)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)

Contemporary oncology (Poznań, Poland), 2017-01, Vol.21 (4), p.285-289

2017

Volltextzugriff (PDF)

399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A424-A424

2020

Volltextzugriff (PDF)

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage

World journal of surgical oncology, 2019-07, Vol.17 (1), p.129-129, Article 129

2019

Volltextzugriff (PDF)

Functional outcome of surgical treatment of adults with extremity osteosarcoma after megaprosthetic reconstruction-single-center experience

Journal of orthopaedic surgery and research, 2019-11, Vol.14 (1), p.346-346, Article 346

2019

Volltextzugriff (PDF)

Automated reasoning based user interface

Expert systems with applications, 2017-04, Vol.71, p.125-137

2017

Volltextzugriff (PDF)

BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells

Molecular oncology, 2020-08, Vol.14 (8), p.1817-1832

2020

Volltextzugriff (PDF)

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Journal of clinical oncology, 2022-03, Vol.40 (7), p.762-771

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Random CNN structure: tool to increase generalization ability in deep learning

The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma

Patient experience of medication administration and development of a Patient Experience and Preference Questionnaire (PEPQ) for patients with advanced or metastatic cancer

Outcome of First‐Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma

IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study

Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Developing Symptom Lists for People with Cancer Treated with Targeted Therapies

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors

Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer

From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)

399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage

Functional outcome of surgical treatment of adults with extremity osteosarcoma after megaprosthetic reconstruction-single-center experience

Automated reasoning based user interface

BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Suchergebnisse filtern